The first batch of financing lasted about five years, but this time around, Sapience Therapeutics thinks its new funding round will have runway for less than two years, until the back half of 2023.
That’s because the Harrison, NY biotech has clinical programs to fund. So, NexPoint is joining existing backers Bristol Myers Squibb, Eshelman Ventures and Kingdon Capital in supplying $41 million for a Series B.
Sapience is going after so-called undruggable targets in cancer by developing small peptides that target protein-protein interactions in the cytoplasm and nucleus. Specifically, Sapience thinks it has the science and tech to go after targets that have been known for decades as “molecular underpinnings” driving cancer but have been unattainable for successful treatments, founder and CEO Barry Kappel told Endpoints News.
READ FULL ARTICLE ON ENDPOINTS NEWS